Stay updated with breaking news from Hartmut Ehrlich. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Abivax expects top-line data from a trial testing its ABX464 anti-infammatory therapy for UC by year's end, with plans to launch a CD trial by mid-2020.
15.11.2022 - EQS-News: ABIVAX / Key word(s): AGM/EGM Abivax releases the results of its November 9, 2022 ad hoc ordinary and extraordinary general meeting 15.11.2022 / 18:00 CET/CEST The issuer is solely responsible for the content of this announcement. ABIVAX ...
DGAP-News: ABIVAX / Key word(s): Half Year Results Abivax presents first-half 2022 financial results and operations update 15....
DGAP-News: ABIVAX / Key word(s): Half Year ResultsAbivax presents first-half 2022 financial results and operations update 15.09.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX PRESENTS FIRST-HALF 2022 FINANCIAL RESULTS AND OPERATIONS UPDATE Obefazimod global piv...
DGAP-News: ABIVAX / Key word(s): MiscellaneousAbivax releases the results of its June 9, 2022 ordinary annual and extraordinary general meeting 10.06.2022 / 18:00 The issuer is solely responsible for the content of this announcement.Abivax releases the results of its June 9, 2022 ordinary annual and extraordinary ge...